Post by lookingforatenbagger on Feb 22, 2023 16:05:26 GMT
Virtually no option vol.
It is basically a zombie company right now. It has revenue, even perhaps significant revenue. But that revenue has declined a lot because a chunk of it was sold off....for what is now valued at virtually nothing. And don't let folks hoodwink you into thinking otherwise with fuzzy math. When one considers the GeneDx sale RATIONALLY, the ineluctable conclusion is that it has been a bust: we've basically burned through, or will soon have burned through, the after tax cash received; and our 80 million shares are worth 38 million bucks. Sure, we'll be getting another 23 million shares, worth about $11 million dollars, soon enough. WGS' stock price has to hit nearly a 'ten bagger' for us just to get back to the total consideration in the original deal terms.
One poster said in the shout box: "NGENLA and Rayaldee royalties are anticipated in FY2023 which will provide earnings." Hmm, they will, presumably provide REVENUE (the amounts if not de minimus only discernible through entail reading and extra sensory perception worthy of Kreskin), but we have no idea, at all, whether those top line monies will generate earnings.
Back to the zombie. We have (reduced) revenue, perhaps/hopefully/St Jude-willing some pockets of growth therein, a LOT of future expense in the form of clinical development costs (a given)with the possibility of a well-heeled partner to bankroll at least some of that. We have fairly significant debt due in two years, over $200 million as we stand today.
Lots COULD happen. But, at present, we are looking at a zombie.....coming to kill us.
it seems to me it belongs in the thread: opkodd.com/thread/18070/opkos-4q22-earnings.